TY - JOUR
T1 - Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats
AU - Fung, Yiu K.
AU - Lau, Yuen Sum
N1 - Funding Information:
This work is supported by a grant from the Smokeless Tobacco Research Council, Inc., New York. We wish to thank the technical assistance of J. Reed, C. Runice and A. Schulte, the secretarial work of E. Manning and the graphical illustrations by K. Theesen. In particular, the advice of Dr. M.J. Marks on the nicotinic receptor binding assay is gratefully acknowledged.
PY - 1988/8/2
Y1 - 1988/8/2
N2 - Rats were pretreated with saline or nicotine (1.5 mg/kg per day) by subcutaneously implanting each animal with an Alzet osmotic mini-pump which continuously released saline or nicotine for 1, 5 and 14 days. At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum. We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day. In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum. The number of striatal [3H]spiperone binding sites was not affected. In animals pretreated with nicotine for 14 days, the nicotine-induced locomotor response remained to be potentiated. However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal. These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.
AB - Rats were pretreated with saline or nicotine (1.5 mg/kg per day) by subcutaneously implanting each animal with an Alzet osmotic mini-pump which continuously released saline or nicotine for 1, 5 and 14 days. At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum. We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day. In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum. The number of striatal [3H]spiperone binding sites was not affected. In animals pretreated with nicotine for 14 days, the nicotine-induced locomotor response remained to be potentiated. However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal. These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.
KW - (Hyperactivity)
KW - Dopamine
KW - Nicotine
KW - Striatum
UR - http://www.scopus.com/inward/record.url?scp=0023766782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023766782&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(88)90721-2
DO - 10.1016/0014-2999(88)90721-2
M3 - Article
C2 - 3220106
AN - SCOPUS:0023766782
SN - 0014-2999
VL - 152
SP - 263
EP - 271
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 3
ER -